| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2 |
| Entrez GeneID | 2719 |
| clone | 7D5E10 |
| WB Predicted band size | 65.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GPC3 (AA: 359-554) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于GPC3抗体的参考文献及其摘要概括：
---
1. **文献名称**: *A humanized glypican-3 antibody as a novel therapeutic agent for hepatocellular carcinoma*
**作者**: Ishiguro T, et al.
**摘要**: 该研究开发了一种人源化抗GPC3单克隆抗体(代号HN3)，在肝癌异种移植模型中显示出显著的抗肿瘤活性。抗体通过抑制GPC3介导的Wnt信号通路并诱导抗体依赖性细胞毒性(ADCC)，为肝癌治疗提供了潜在新策略。
2. **文献名称**: *Glypican-3-targeted therapy in hepatocellular carcinoma: mechanisms and clinical implications*
**作者**: Feng M, et al.
**摘要**: 本文综述了GPC3在肝细胞癌中的特异性表达及其作为治疗靶点的潜力，重点讨论了抗GPC3抗体的作用机制(如免疫偶联药物和双特异性抗体)，并总结了早期临床试验的疗效与安全性数据。
3. **文献名称**: *CAR-T cells targeting GPC3 in hepatocellular carcinoma: preclinical and clinical progress*
**作者**: Zhu Y, et al.
**摘要**: 研究利用抗GPC3单链抗体(scFv)构建CAR-T细胞，通过体外和小鼠模型验证其对GPC3阳性肝癌细胞的特异性杀伤效果，初步临床数据显示部分患者肿瘤缩小，提示靶向GPC3的免疫治疗前景。
4. **文献名称**: *Development of a GPC3-specific monoclonal antibody for molecular imaging and therapy*
**作者**: Li W, et al.
**摘要**: 该团队开发了一种新型抗GPC3单克隆抗体YP7.通过放射性标记(如¹³¹I)实现肝癌的精准分子影像诊断，并探索其作为抗体药物偶联物(ADC)在靶向治疗中的应用潜力。
---
以上文献涵盖抗体治疗、分子机制、免疫疗法(CAR-T)及诊断应用，反映了GPC3抗体在肝癌领域的研究进展。如需具体文章链接或补充信息，可进一步说明。
Glypican-3 (GPC3), a member of the glypican family of heparan sulfate proteoglycans, is anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) moiety. It plays roles in regulating cellular signaling pathways, including Wnt, Hedgehog, and fibroblast growth factor, influencing cell proliferation, survival, and differentiation. Notably, GPC3 is highly expressed in various cancers, particularly hepatocellular carcinoma (HCC), while showing minimal or no expression in normal adult tissues. This tumor-specific overexpression makes GPC3 a promising diagnostic biomarker and therapeutic target.
GPC3-targeting antibodies have emerged as key tools in oncology. Diagnostically, they enable immunohistochemical detection of GPC3 in tumor biopsies, aiding HCC differentiation from benign liver conditions. Therapeutically, monoclonal antibodies (e.g., codrituzumab, YP7) are designed to bind GPC3. either directly inhibiting tumor growth or delivering cytotoxic payloads. Bispecific antibodies and antibody-drug conjugates (ADCs) leveraging GPC3 specificity are under investigation. Additionally, GPC3 serves as a target for CAR-T cell therapies, showing preclinical efficacy in solid tumors.
Despite progress, challenges persist. Heterogeneous GPC3 expression in tumors and potential on-target/off-tumor effects require careful patient stratification. Ongoing clinical trials aim to optimize safety and efficacy, positioning GPC3 antibodies as potential breakthroughs in precision cancer treatment.
×
